BWX Technologies and Fusion Pharmaceuticals partner in actinium-225 production

BWX Technologies (BWXT) subsidiary BWXT Medical and Fusion Pharmaceuticals (FUSN) have entered into an agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials. BWXT Medical will provide Fusion with a preferential supply of radium-225 and access to high-specific activity generator technology – actinium-227-free -, enabling Fusion to produce actinium-225 at its Good Manufacturing Practice manufacturing facility for the benefit of its clinical trials. In addition, the companies have expanded their existing actinium-225 supply agreement, supporting Fusion’s advancing pipeline of targeted alpha therapies. In January, Fusion and BWXT Medical entered into a preferred partner agreement for the supply of actinium-225. Under that agreement, BWXT Medical has been providing predetermined amounts of Fusion’s actinium supply needs at volume-based pricing.